AU2001261218A1 - Peptide deformylase inhibitors - Google Patents

Peptide deformylase inhibitors

Info

Publication number
AU2001261218A1
AU2001261218A1 AU2001261218A AU6121801A AU2001261218A1 AU 2001261218 A1 AU2001261218 A1 AU 2001261218A1 AU 2001261218 A AU2001261218 A AU 2001261218A AU 6121801 A AU6121801 A AU 6121801A AU 2001261218 A1 AU2001261218 A1 AU 2001261218A1
Authority
AU
Australia
Prior art keywords
hydroxy
formyl
ethylamine
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261218A
Other languages
English (en)
Inventor
Kelly M. Aubart
Jacques Briand
Siegfried B. Christensen Iv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2001261218A1 publication Critical patent/AU2001261218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2001261218A 2000-05-05 2001-05-04 Peptide deformylase inhibitors Abandoned AU2001261218A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20194300P 2000-05-05 2000-05-05
US60201943 2000-05-05
US23808400P 2000-10-04 2000-10-04
US60238084 2000-10-04
PCT/US2001/014593 WO2001085170A1 (fr) 2000-05-05 2001-05-04 Inhibiteurs de peptide deformylase

Publications (1)

Publication Number Publication Date
AU2001261218A1 true AU2001261218A1 (en) 2001-11-20

Family

ID=26897227

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261218A Abandoned AU2001261218A1 (en) 2000-05-05 2001-05-04 Peptide deformylase inhibitors

Country Status (20)

Country Link
US (2) US6806369B2 (fr)
EP (1) EP1283711B1 (fr)
JP (1) JP2003532677A (fr)
KR (1) KR20020093127A (fr)
CN (1) CN1427721A (fr)
AR (1) AR029916A1 (fr)
AT (1) ATE389403T1 (fr)
AU (1) AU2001261218A1 (fr)
BR (1) BR0110206A (fr)
CA (1) CA2408236A1 (fr)
CZ (1) CZ20023618A3 (fr)
DE (1) DE60133273T2 (fr)
ES (1) ES2300330T3 (fr)
HU (1) HUP0302505A2 (fr)
IL (1) IL152638A0 (fr)
MX (1) MXPA02010843A (fr)
NO (1) NO20025281L (fr)
NZ (1) NZ521560A (fr)
PL (1) PL359865A1 (fr)
WO (1) WO2001085170A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4220377B2 (ja) * 2001-04-05 2009-02-04 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害物質
EP1399416B1 (fr) * 2001-06-05 2011-11-02 GlaxoSmithKline LLC Inhibiteur de la deformylase peptidique
WO2004052919A2 (fr) * 2002-12-11 2004-06-24 Smithkline Beecham Corporation Inhibiteurs de peptide deformylase
EP1683521A1 (fr) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Inhibiteurs de la peptide deformylase, leur utilisations et compositions pharmacéutiques qui les contiennent
DE102005019181A1 (de) 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
JP2008538776A (ja) * 2005-04-25 2008-11-06 ノバルティス アクチエンゲゼルシャフト ペプチド脱ホルミル酵素（ｐｄｆ）阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体
US7705037B2 (en) * 2005-06-07 2010-04-27 Novartis Ag 1-substituted pyrrolidin-2-ones and use thereof as peptide deformylase inhibitors
WO2007040289A1 (fr) * 2005-10-05 2007-04-12 Promeditech Inc. Inhibiteur de la déformylase, procédé de préparation de celui-ci et composition le comprenant
KR100753796B1 (ko) * 2006-07-28 2007-08-31 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282986A (en) * 1960-10-06 1966-11-01 Merck & Co Inc N-acylated hydroxamic acids and derivatives thereof
EP0196184B1 (fr) 1985-03-16 1992-09-16 The Wellcome Foundation Limited Dérivés arylés
GB8531838D0 (en) * 1985-12-30 1986-02-05 Wellcome Found Aryl derivatives
PL154186B1 (en) 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
NZ501166A (en) 1997-07-31 2001-12-21 Abbott Lab Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
CN1298299A (zh) 1998-02-07 2001-06-06 英国生物技术药物有限公司 抗菌剂
AR028075A1 (es) * 2000-05-05 2003-04-23 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
US20040034024A1 (en) 2001-05-04 2004-02-19 Aubart Kelly M Peptide deformylase inhibitors

Also Published As

Publication number Publication date
JP2003532677A (ja) 2003-11-05
US6806369B2 (en) 2004-10-19
CN1427721A (zh) 2003-07-02
CA2408236A1 (fr) 2001-11-15
WO2001085170A1 (fr) 2001-11-15
EP1283711B1 (fr) 2008-03-19
CZ20023618A3 (cs) 2003-09-17
US20040053932A1 (en) 2004-03-18
PL359865A1 (en) 2004-09-06
AR029916A1 (es) 2003-07-23
ES2300330T3 (es) 2008-06-16
US7115605B2 (en) 2006-10-03
EP1283711A1 (fr) 2003-02-19
DE60133273D1 (de) 2008-04-30
NO20025281L (no) 2003-01-03
NO20025281D0 (no) 2002-11-04
KR20020093127A (ko) 2002-12-12
IL152638A0 (en) 2003-06-24
BR0110206A (pt) 2003-01-28
HUP0302505A2 (hu) 2003-12-29
DE60133273T2 (de) 2009-03-05
NZ521560A (en) 2004-05-28
WO2001085170A9 (fr) 2006-01-26
EP1283711A4 (fr) 2003-05-21
US20040192719A1 (en) 2004-09-30
MXPA02010843A (es) 2003-03-27
ATE389403T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
US6806369B2 (en) Peptide deformylase inhibitors
US7745637B2 (en) Peptide deformylase inhibitors
EP1283709B1 (fr) Inhibiteurs de la peptide deformylase
US20040267015A1 (en) Peptide deformylase inhibitors
EP1399416B1 (fr) Inhibiteur de la deformylase peptidique
US6797730B2 (en) Peptide deformylase inhibitors
US20040034024A1 (en) Peptide deformylase inhibitors
JP2005532358A (ja) ペプチドデホルミラーゼ阻害剤